Presynaptic nigro-striatal function in a group of Alzheimer's disease patients with parkinsonism: evidence from a dopamine transporter imaging study

Presynaptic nigro-striatal function in a group of Alzheimer's disease patients with parkinsonism: evidence from a dopamine transporter imaging study
复制标题

DOI:
10.1007/s00702-004-0140-0
复制
发表时间:
2004-08-01
影响因子:
3.3
通讯作者:
Murri, L
Murri, L
中科院分区:
医学3区
文献类型:
--
作者:
Ceravolo, R;Volterrani, D;Murri, L

文献摘要

被引文献

相似文献

阿尔茨海默病(AD)中帕金森病的发生是相当普遍的,然而,AD中锥体外系特征背后的分子和神经化学变化尚未完全了解。关于阿尔茨海默病中多巴胺能变化的存在,死后和体内成像研究产生了相互矛盾的结果。本研究旨在探讨AD合并帕金森病患者体内黑质纹状体多巴胺能功能的变化。13例AD患者和与既往使用抗精神病药(AD- p)无关的锥体外系特征进行了多巴胺转运体配体I-123-FP-CIT SPECT检查,并将数据与15例弥漫性路易体痴呆(DLBD)患者、20例帕金森病(PD)患者和8例健康老年人对照进行了比较。数据分析采用感兴趣区域方法进行,并计算纹状体与非特异性(枕叶)放射性比。AD-P患者的I-123-FP-CIT纹状体摄取与对照人群相似。与AD-P组和对照组相比,DLBD组和PD组在所有纹状体区域的I-123-FP-CIT摄取均显著降低(p < 0.05)
The occurrence of parkinsonism in Alzheimer's disease (AD) is quite common, however the molecular and neurochemical changes underlying such extrapyramidal features in AD have been not fully understood. Post-mortem as well as in vivo imaging study have produced conflicting results as regards the existence of dopaminergic changes in AD. Aim of the present study was to investigate in vivo the nigro-striatal dopaminergic function in a group of AD patients with parkinsonism. Thirteen patients with AD and extrapyramidal features not related to past neuroleptic use (AD-P) underwent SPECT with I-123-FP-CIT, a ligand of dopamine transporter, and the data were compared with those obtained in 15 patients with Diffuse Lewy Body Dementia (DLBD), 20 patients with Parkinson's disease (PD), and 8 healthy elderly controls. The analysis of the data was performed by regions-of-interest approach and calculations of the striatal-to-non specific (occipital lobes) radioactivity ratios were made. The I-123-FP-CIT striatal uptake in patients with AD-P was similar to that obtained in the control population. Both the DLBD and PD groups showed significantly lower I-123-FP-CIT uptake in all striatal areas with respect to AD-P and control groups (p